DMRA · Damora Therapeutics, Inc. · Financials
$28.10
+1.26 (+4.69%)
At close · Sep 11
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.73B
Shares
61.74M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$209.84M
-878.8%
FY2025
Diluted EPS
$3.98
+121.5%
FY2025
Operating Cash Flow
-$6.73M
+63.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $8.17M | $1.17M | $844K | $1.69M | $722K | $156K | — | — | |
| $74.05M | $26.88M | $6.4M | $23.77M | $48.21M | $38.49M | $24.63M | $19.74M | |
| $22.3M | $9.69M | $10.5M | $12.69M | $13M | $13.74M | $9.01M | $2.45M | |
| — | — | $968K | $3.45M | — | — | — | — | |
| $270.66M | $210.87M | $22.26M | $39.91M | $61.21M | $52.23M | $33.64M | $38.97M | |
| -$270.66M | -$210.87M | -$22.26M | -$39.91M | -$61.21M | -$52.23M | -$33.64M | $38.97M | |
| $8.17M | $1.08M | $862K | $1.56M | -$417K | $475K | -$1.2M | $2.46M | |
| -$262.49M | -$209.79M | -$21.4M | -$38.35M | -$61.62M | -$51.75M | -$34.84M | -$36.51M | |
| $341K | $50K | $41K | $0 | $0 | $0 | $0 | $0 | |
| -$262.83M | -$209.84M | -$21.44M | -$38.35M | -$61.62M | -$51.75M | -$34.84M | -$36.51M | |
| — | — | — | — | — | — | -$34.84M | -$42.07M | |
| -$262.9M | -$209.13M | -$21.72M | -$37.73M | -$61.55M | -$52.75M | -$31.71M | -$37.31M | |
| USD/shares | $7.49 | $3.98 | -$18.53 | -$36.08 | -$60.75 | -$51.25 | — | — |
| USD/shares | $7.49 | $3.98 | -$18.53 | -$36.08 | -$60.75 | -$51.25 | — | — |
| shares | — | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M | 182.91K | 10.4K |
| shares | — | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M | 182.91K | 10.4K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.02×
EV/EBIT
—
Peer median 16.61×
P/E (TTM)
—
Peer median 17.56×
Peer medians compare against the 267 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1800315
CUSIP
G2646Y104
13F (30d)
52 filings
52 filers
Visit website
Investor relations